Treatment of Refractory Insomnia with Pharmacological Agents

Introduction to Treatment Options

The American Academy of Sleep Medicine recommends suvorexant (an orexin receptor antagonist) for sleep maintenance insomnia, or low-dose doxepin (3-6 mg) as an alternative second-line agent, for patients who have failed eszopiclone, gabapentin, clonazepam, and zolpidem 1, 2

Suvorexant is specifically indicated for sleep maintenance insomnia and reduces wake time after sleep onset by 16-28 minutes compared to placebo 2
Low-dose doxepin (3-6 mg) is recommended by the American Academy of Sleep Medicine as a second-line option specifically for sleep maintenance insomnia 1
Temazepam 15 mg can be considered for both sleep onset and maintenance, as an intermediate-acting benzodiazepine 1
Zaleplon 10 mg can be used if there is any sleep onset component remaining 1

Suvorexant improves subjective total sleep time by 22.3-49.9 minutes at doses of 10-20 mg 2
Suvorexant should be reevaluated after 7-10 days if insomnia persists to rule out comorbid conditions 2
Low-dose doxepin (3-6 mg) works through histamine H1 receptor antagonism at low doses, different mechanism than previously tried agents 1

Combination of BzRA + Antidepressant may improve efficacy by targeting multiple sleep-wake mechanisms while minimizing toxicity from higher doses of single agents 3
Low doses of antidepressants typical for insomnia treatment should be used, but carefully monitor for daytime sedation 3

If insomnia persists after 7-10 days of appropriate treatment, reevaluate for comorbid sleep disorders such as restless legs syndrome and obstructive sleep apnea 2
Cognitive Behavioral Therapy for Insomnia (CBT-I) should be implemented alongside any pharmacotherapy as it has superior long-term efficacy compared to medications alone 1

Trazodone is not recommended by the American Academy of Sleep Medicine for sleep onset or maintenance insomnia despite common off-label use 1
Tiagabine is not recommended due to insufficient evidence and risk of seizures 1, 3
Quetiapine or olanzapine have insufficient evidence for primary insomnia and significant risk of neurological side effects, weight gain, and metabolic dysfunction 1, 3
Over-the-counter antihistamines are not recommended due to lack of efficacy data and safety concerns 1

Regular follow-up is essential during initial treatment to assess effectiveness and side effects 1
Medications should be tapered when conditions allow to prevent discontinuation symptoms 1
Patients should be educated about treatment goals, safety concerns, and potential side effects of new agents 1